Research · 6 min read
What a Research Use Only Label Does Not Do
Federal law decides what an article is by what it is intended for, and a regulation defines that intent by objective evidence — including the circumstances of distribution. A disclaimer is one piece of evidence among several.
Key takeaways
- The statutory definition of a drug turns on what an article is intended for, so classification can never rest on chemistry alone.
- 21 CFR 201.128 defines intended use as objective intent shown by expressions, design or composition, or the circumstances surrounding distribution.
- The same regulation says objective intent may be shown by circumstances in which an article is knowingly offered or used for a purpose it is neither labeled nor advertised for.
- It also limits itself: a firm is not treated as intending an unapproved new use of an approved drug based solely on knowing that providers prescribe it that way.
- Intended use can change downstream — a packer, distributor or seller intending a different use must supply adequate labeling for that new use.
- The two research-style cautions written into the regulations, in 312.160 and 201.122, are conditions on shipment within a supply chain, and both come with duties on the shipper.
Answer first: intent is in the definition, and the definition is objective
The word drug is defined by intent. Under 21 U.S.C. 321(g)(1), the term means, among other things, "articles intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease in man or other animals," and "articles (other than food) intended to affect the structure or any function of the body of man or other animals." Intended appears in both clauses. Whether something is a drug is therefore never settled by chemistry alone.
The regulation that defines intent for labeling purposes is 21 CFR 201.128, headed "Meaning of 'intended uses'." It says the phrase refers to "the objective intent of the persons legally responsible for the labeling of an article (or their representatives)." And it lists how that intent may be shown: "The intent may be shown by such persons' expressions, the design or composition of the article, or by the circumstances surrounding the distribution of the article. This objective intent may, for example, be shown by labeling claims, advertising matter, or oral or written statements by such persons or their representatives."
Read that list again. Labeling claims are one of five named categories. Design or composition is another. Circumstances surrounding distribution is another. Nothing in the regulation makes any single statement dispositive, and nothing in it says a disclaimer settles the question.
The sentence about circumstances, and the limit written next to it
The regulation goes further than the list. It continues: "Objective intent may be shown, for example, by circumstances in which the article is, with the knowledge of such persons or their representatives, offered or used for a purpose for which it is neither labeled nor advertised."
That clause is doing something specific. It describes a situation where the label says one thing and the surrounding circumstances say another, and it treats the circumstances as evidence of intent.
The same sentence carries an express limit, and the limit deserves as much attention as the rule. It ends: "provided, however, that a firm would not be regarded as intending an unapproved new use for an approved drug based solely on that firm's knowledge that such drug was being prescribed or used by health care providers for such use." So mere knowledge that prescribers are using an approved drug off-label does not, by itself, convert the manufacturer's intent. The regulation distinguishes between knowing what other people do and doing something oneself.
There is one more sentence, and it is the one that matters for anyone who resells. "The intended uses of an article may change after it has been introduced into interstate commerce by its manufacturer. If, for example, a packer, distributor, or seller intends an article for different uses than those intended by the person from whom he or she received the article, such packer, distributor, or seller is required to supply adequate labeling in accordance with the new intended uses." Intended use travels down the chain and can be created by a reseller who had nothing to do with making the substance.
The research cautions that actually exist in the regulations
Two required caution statements in Title 21 are commonly paraphrased as research use only, and neither is a license to sell.
The first is for material shipped for laboratory testing. Under 21 CFR 312.160, a person may ship a drug "intended solely for tests in vitro or in animals used only for laboratory research purposes" if it bears this label: "CAUTION: Contains a new drug for investigational use only in laboratory research animals, or for tests in vitro. Not for use in humans." The permission comes with duties. The shipper "shall use due diligence to assure that the consignee is regularly engaged in conducting such tests and that the shipment of the new drug will actually be used for tests in vitro or in animals used only for laboratory research," must keep records naming each recipient and each shipment for two years, and must let FDA inspect them. FDA may terminate the authorization to ship if the conditions are not met, or if "the drug is used for purposes other than bona fide scientific investigation."
The second is for bulk material heading into manufacturing. Under 21 CFR 201.122, a drug in a bulk package intended for processing, repacking or use in making another drug is exempt from the adequate-directions requirement if its label bears "Caution: For manufacturing, processing, or repacking" — plus, where the dosage forms would be prescription drugs, the statement "Rx only." That exemption does not apply where the intended use in manufacturing causes the finished article to be a new drug, except in the narrow circumstances the section then lists, such as an approved application covering the delivery of the substance to the application holder.
Both sentences are addressed to a supply chain, not to a consumer. Each is a statement that the article is outside the approved supply, and each comes attached to obligations on whoever ships it.
Why the label alone cannot resolve the question
The structure of the act explains why. The prohibited-acts section, 21 U.S.C. 331, forbids "The introduction or delivery for introduction into interstate commerce of any food, drug, device, tobacco product, or cosmetic that is adulterated or misbranded," the adulteration or misbranding of such an article in interstate commerce, the receipt of such an article and its delivery or proffered delivery for pay or otherwise, and "The introduction or delivery for introduction into interstate commerce of any article in violation of section 344, 350d, 355," and other named sections.
Each of those turns on what the article is. If the article is a drug — and whether it is a drug depends on intended use — then the approval requirement in section 355, the misbranding provisions in section 352, and the prescription-drug provisions in section 353 come into play. A statement printed on a vial does not decide the antecedent question; the objective-intent test does.
This is also why the labeling regulations treat exemptions as conditional rather than absolute. Section 201.115 exempts a new drug from the adequate-directions requirement only to the extent claimed in an approved application, or where no application is approved but the drug complies with the investigational provisions — and it closes with a flat sentence: "No exemption shall apply to any other drug which would be a new drug if its labeling bore representations for its intended uses."
What a reader can take from this
This site does not classify any seller's product and takes no position on any individual case. The value of these provisions to a reader is that they replace a vague impression with a set of specific, checkable questions.
What does the seller's own material say the article is for — its expressions, its advertising, its written statements. What is the design and composition of the thing being sold: a bulk chemical, or something presented in a form a person could administer. And what are the circumstances surrounding distribution, which the regulation names as evidence in its own right.
The regulation also answers a question people often ask backwards. A disclaimer does not create a safe category; it is one of the expressions that a regulator would read alongside everything else. And because intended use can change downstream, a reseller cannot rely on the intent of whoever supplied it — the regulation says a packer, distributor or seller who intends a different use is required to supply adequate labeling for that new intended use.
Nothing in these provisions says anything about whether a substance is safe, whether it is what it claims to be, or whether it does anything. Those are separate questions, and this article does not answer them.
Sources
- 21 CFR Part 201 — Labeling (sections 201.5, 201.115, 201.122 and 201.128)The full text of the meaning of intended uses in 201.128, including the list of evidence, the clause about circumstances of distribution, the limit regarding knowledge of off-label prescribing, and the sentence on intended uses changing downstream; the bulk-package caution and its conditions in 201.122; and the conditional new-drug exemption and closing sentence in 201.115.
- 21 CFR Part 312 — Investigational New Drug Application (section 312.160, Drugs for investigational use in laboratory research animals or in vitro tests)The required caution statement for material shipped for in vitro or laboratory-animal testing; the shipper's due-diligence obligation regarding the consignee; the two-year record requirement and FDA access to those records; and FDA's authority to terminate the authorization to ship, including where the drug is used for purposes other than bona fide scientific investigation.
- 21 U.S.C. 321 — Definitions; generally (subsection (g)(1))The definition of drug, including the clauses covering articles intended for use in the diagnosis, cure, mitigation, treatment or prevention of disease and articles intended to affect the structure or any function of the body.
- 21 U.S.C. 331 — Prohibited acts (subsections (a) through (d))The prohibitions on introducing or delivering for introduction into interstate commerce an adulterated or misbranded article, on adulterating or misbranding an article in interstate commerce, on receiving such an article and delivering it for pay or otherwise, and on introducing an article in violation of the named sections including section 355.
Frequently asked questions
Does labeling something research use only keep it from being a drug?
The regulation on intended uses says intent is shown by expressions, the design or composition of the article, or the circumstances surrounding distribution, and gives labeling claims, advertising and oral or written statements as examples. A label is evidence within that framework rather than a rule that overrides it.
What is the actual research caution in the regulations?
Section 312.160 permits shipment of a drug intended solely for tests in vitro or in laboratory research animals if it is labeled: CAUTION: Contains a new drug for investigational use only in laboratory research animals, or for tests in vitro. Not for use in humans. The shipper must use due diligence about the recipient, keep records of shipments for two years, and permit FDA to inspect them.
Can a seller be treated as intending a use it never advertised?
The regulation states that objective intent may be shown by circumstances in which the article is, with the knowledge of the persons responsible or their representatives, offered or used for a purpose for which it is neither labeled nor advertised. The same sentence adds that a firm is not regarded as intending an unapproved new use of an approved drug based solely on knowing that health care providers prescribe it that way.
Does intended use follow the product down the supply chain?
Yes, in the sense the regulation describes. It states that intended uses may change after an article has been introduced into interstate commerce, and that a packer, distributor or seller who intends the article for different uses than the person it came from is required to supply adequate labeling in accordance with the new intended uses.
What does the bulk caution mean when it appears on a container?
Section 201.122 exempts a bulk package intended for processing, repacking or use in manufacturing another drug from the adequate-directions requirement if its label states Caution: For manufacturing, processing, or repacking, with an Rx only statement where the dispensed dosage forms would be prescription drugs. The exemption is narrowed where the intended manufacturing use makes the finished article a new drug.
Does any of this tell me whether a substance is safe?
No. These provisions govern classification, labeling and lawful distribution. They say nothing about the contents, purity or effects of any particular article, and this site makes no claim about any product sold under a research label.